Abeona Therapeutics (NASDAQ:ABEO – Get Free Report)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They currently have a $36.00 price objective on the biopharmaceutical company’s stock.
Separately, StockNews.com downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday.
Read Our Latest Report on Abeona Therapeutics
Abeona Therapeutics Price Performance
Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last announced its quarterly earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.13). As a group, sell-side analysts expect that Abeona Therapeutics will post -1.83 earnings per share for the current year.
Institutional Trading of Abeona Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of ABEO. Adage Capital Partners GP L.L.C. grew its holdings in Abeona Therapeutics by 84.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 3,249,994 shares of the biopharmaceutical company’s stock worth $13,682,000 after acquiring an additional 1,488,834 shares during the period. AIGH Capital Management LLC boosted its stake in shares of Abeona Therapeutics by 77.7% in the 3rd quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company’s stock worth $4,779,000 after buying an additional 496,278 shares during the last quarter. Citigroup Inc. lifted its stake in Abeona Therapeutics by 125.0% in the third quarter. Citigroup Inc. now owns 450,000 shares of the biopharmaceutical company’s stock valued at $1,894,000 after purchasing an additional 250,000 shares during the last quarter. Barclays PLC raised its holdings in Abeona Therapeutics by 100.0% during the 3rd quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock valued at $1,564,000 after acquiring an additional 185,638 shares during the period. Finally, Worth Venture Partners LLC raised its holdings in Abeona Therapeutics by 76.6% during the 3rd quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock valued at $1,184,000 after acquiring an additional 121,969 shares during the period. 80.56% of the stock is currently owned by institutional investors and hedge funds.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Recommended Stories
- Five stocks we like better than Abeona Therapeutics
- How to Effectively Use the MarketBeat Ratings Screener
- High-Yield Texas Instruments Could Hit New Highs Soon
- How to Most Effectively Use the MarketBeat Earnings Screener
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- How is Compound Interest Calculated?
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.